المؤلفون: Bart Neyns, Christian U. Blank, Michal Lotem, Mark R. Middleton, J.-J. Grob, Melanie A. Leiby, Antoni Ribas, C. Robert, Jacob Schachter, Céleste Lebbé, Euan Walpole, Matteo S. Carlino, Neil Steven, Nageatte Ibrahim, Peter Mohr, A. Arance, Paul Lorigan, Mario Sznol, Erin Jensen, Georgina V. Long, Laurent Mortier

المساهمون: Faculty of Law and Criminology, Medical Oncology, Clinical sciences, Laboratory of Molecular and Medical Oncology, Faculty of Arts and Philosophy

المصدر: Long, G V, Arance, A, Mortier, L, Lorigan, P, Blank, C, Mohr, P, Schachter, J, Grob, J-J, Lotem, M, Middleton, M R, Neyns, B, Steven, N, Ribas, A, Walpole, E, Carlino, M S, Lebbe, C, Sznol, M, Jensen, E, Leiby, M A, Ibrahim, N & Robert, C 2022, ' Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma : analysis from KEYNOTE-006 ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 204-215 . https://doi.org/10.1016/j.annonc.2021.10.010Test

مصطلحات موضوعية: Proto-Oncogene Proteins B-raf, advanced melanoma, Oncology, BRAF inhibition, medicine.medical_specialty, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Internal medicine, medicine, Humans, In patient, ipilimumab, Melanoma, Complete response, Advanced melanoma, Mitogen-Activated Protein Kinase Kinases, Antitumor activity, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Hematology, medicine.disease, MEK inhibition, pembrolizumab, business, Progressive disease, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ae40264769d12ae7ca2fde50f109b8fTest
https://doi.org/10.1016/j.annonc.2021.10.010Test

المؤلفون: Christian U. Blank, John B. A. G. Haanen, Doranne L. Hilarius, Michel W. J. M. Wouters, Willeke A. M. Blokx, Franchette W P J van den Berkmortel, Ellen Kapiteijn, Rawa K. Ismail, Geke A. P. Hospers, Jesper van Breeschoten, Alfonsus J. M. van den Eertwegh, Rozemarijn S. van Rijn, Jan Willem B. de Groot, Maureen J.B. Aarts, D Piersma, Astrid A M van der Veldt, G. Vreugdenhil, Marion A. M. Stevense-den Boer, Marye Boers-Sonderen, Karijn P M Suijkerbuijk, Olivier J. van Not, Melissa M. De Meza

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Medical Oncology, Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D)

المصدر: International Journal of Cancer, 150(5), 816-824. Wiley
van Not, O J, van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, de Meza, M M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Blokx, W A M, Suijkerbuijk, K P M & Wouters, M W J M 2022, ' The unfavorable effects of COVID-19 on Dutch advanced melanoma care ', International Journal of Cancer, vol. 150, no. 5, pp. 816-824 . https://doi.org/10.1002/ijc.33833Test
International Journal of Cancer, 150, 816-824
International Journal of Cancer, 150, 5, pp. 816-824
International Journal of Cancer, 150(5), 816-824. Wiley-Liss Inc.
International Journal of Cancer, 150(5), 816-824. WILEY
International Journal of Cancer

مصطلحات موضوعية: Adult, Male, advanced melanoma, Cancer Research, Pediatrics, medicine.medical_specialty, Skin Neoplasms, Coronavirus disease 2019 (COVID-19), IMPACT, nationwide registry, Medical care, Systemic therapy, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], systemic therapy, SDG 3 - Good Health and Well-being, COVID‐19, Humans, Medicine, Stage IIIC, Cancer Therapy and Prevention, Melanoma, Aged, Netherlands, Advanced melanoma, Aged, 80 and over, Control period, Performance status, SARS-CoV-2, business.industry, COVID-19, Middle Aged, medicine.disease, clinical outcomes, Oncology, Female, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6999d1436b905ac42aa992a91b031b28Test
https://hdl.handle.net/2066/244556Test

المؤلفون: Debbie van Baarle, Nynke Y. Rots, Mathilda Jalving, Christian U. Blank, Elisabeth G.E. de Vries, Guus F. Rimmelzwaan, Tatjana T Westphal, Cecile A C M van Els, Anne-Marie C. Dingemans, John B. A. G. Haanen, T. Jeroen N. Hiltermann, Egbert F. Smit, Rudolf S N Fehrmann, Arkajyoti Bhattacharya, Rob van Binnendijk, Astrid A M van der Veldt, Gerco den Hartog, Anke Huckriede, Pia Kvistborg, Corine H. GeurtsvanKessel, Sjoukje F. Oosting, Marion Koopmans, Marieke van der Heiden

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Translational Immunology Groningen (TRIGR), Targeted Gynaecologic Oncology (TARGON), Microbes in Health and Disease (MHD), Medical Oncology, Radiology & Nuclear Medicine, Virology, Pulmonary Medicine

المصدر: Lancet Oncology, 22(12), 1681-1691. ELSEVIER SCIENCE INC
The Lancet Oncology, 22(12), 1681-1691. Lancet Publishing Group
The Lancet. Oncology

مصطلحات موضوعية: Male, medicine.medical_specialty, Antineoplastic Agents, Antibodies, Viral, Injections, Intramuscular, Cohort Studies, Immunomodulation, Interferon-gamma, Immunogenicity, Vaccine, SDG 3 - Good Health and Well-being, Chemoimmunotherapy, Neoplasms, Surveys and Questionnaires, VACCINES, Internal medicine, medicine, Clinical endpoint, Humans, Prospective Studies, Seroconversion, Adverse effect, Aged, Netherlands, SARS-CoV-2, business.industry, Vaccination, COVID-19, Cancer, Articles, Middle Aged, medicine.disease, Combined Modality Therapy, CANCER, Oncology, Cohort, Female, Immunotherapy, business, Febrile neutropenia, 2019-nCoV Vaccine mRNA-1273, RESPONSES

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b729685410a8953022f09c2f02822a62Test
https://doi.org/10.1016/s1470-2045Test(21)00574-x

المؤلفون: Christian U. Blank, Paulien Cornelissen-Steijger, Aida Shahrabi, Oscar Krijgsman, Petra Ross-Macdonald, Daniel S. Peeper, John B. A. G. Haanen, Martin Del Castillo Velasco-Herrera, Kristel Kemper, Maarten A. Ligtenberg, Sofia Ibanez Molero, David W. Vredevoogd, Julia Boshuizen, Roelof J.C. Kluin, Ji-Ying Song, Thomas Kuilman, Elisa A. Rozeman, Beaunelle de Bruijn, David J. Adams

المصدر: Clinical Cancer Research. 27:5389-5400

مصطلحات موضوعية: Cancer Research, business.industry, Melanoma, Programmed Cell Death 1 Receptor, Cell, RNA, medicine.disease, Immune checkpoint, Blockade, Transplantation, Mice, medicine.anatomical_structure, Oncology, CTLA-4, Tumor Microenvironment, Cancer research, Animals, Humans, Medicine, Cytotoxic T cell, CTLA-4 Antigen, business, Immune Checkpoint Inhibitors

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5f4efae16e2251e152c52de002875ffTest
https://doi.org/10.1158/1078-0432.ccr-20-4218Test

المؤلفون: Simone Brokamp, Annegien Broeks, Christian U. Blank, Petra Herzig, Marlous van den Braber, Daniela S. Thommen, Alfred Zippelius, Marjolein de Bruijn, Joyce Sanders, Ton N. Schumacher, Lisanne M. Roelofsen, Koen J. Hartemink, John B. A. G. Haanen, Kim Monkhorst, Paula Voabil, Sanne H. Hendriks

المصدر: Nature Medicine. 27:1250-1261

مصطلحات موضوعية: business.industry, medicine.medical_treatment, Cell, Cancer, General Medicine, Immunotherapy, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Blockade, medicine.anatomical_structure, Immune system, Cell culture, medicine, Cancer research, Pd 1 blockade, business, Ex vivo

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::c45c19b51a9c099f12311a77da46c458Test
https://doi.org/10.1038/s41591-021-01398-3Test

المؤلفون: Céleste Lebbé, Ines Pires da Silva, Irene L.M. Reijers, Megan Lyle, Alexander M. Menzies, Alison Weppler, Shahneen Sandhu, Camille L. Gerard, Matteo S. Carlino, Joanna Mangana, Douglas B. Johnson, Patricio Serra-Bellver, Oliver Klein, James R. Patrinely, Andrew Haydon, Tasnia Ahmed, Olivier Michielin, Khang Nguyen, Claudia Trojaniello, Paul Lorigan, Allison Betof Warner, Dan Stout, Clara Allayous, Christian U. Blank, Paolo A. Ascierto, Lisa Zimmer, Serigne Lo, Georgina V. Long

المصدر: The Lancet Oncology. 22:836-847

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, Programmed Cell Death 1 Receptor, Medizin, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, Positron Emission Tomography Computed Tomography, Internal medicine, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, Progression-free survival, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Melanoma, Aged, Retrospective Studies, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Progression-Free Survival, Nivolumab, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9178dd6e7066c6eafdc578a3589333b7Test
https://doi.org/10.1016/s1470-2045Test(21)00097-8

المؤلفون: Christian U. Blank, Thomas Powles, John Wagstaff, Sylvie Rottey, Maureen J.B. Aarts, Peter F.A. Mulders, Igle J. de Jong, Jean-Baptiste Lattouf, Lori Wood, John B. A. G. Haanen, Harm H.E. van Melick, Michael Jewett, Axel Bex, Patricia J. Zondervan, Yasmin Abu-Ghanem, Johannes V. Van Thienen, Anouk Neven, Bertrand Tombal, Laurence Collette

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Urology, APH - Personalized Medicine, APH - Quality of Care

المصدر: BJU International, 130(1), 68-75. Wiley
BJU International, 130, 68-75
BJU International, 130, 1, pp. 68-75
BJU international. Wiley-Blackwell

مصطلحات موضوعية: medicine.medical_specialty, renal cell carcinoma, #uroonc, Urology, sunitinib, Population, PLANNED NEPHRECTOMY, urologic and male genital diseases, Systemic therapy, Nephrectomy, survival, TARGETED THERAPY, RENAL-CELL CARCINOMA, Renal cell carcinoma, Post-hoc analysis, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, Humans, Cytoreductive nephrectomy, education, Carcinoma, Renal Cell, education.field_of_study, #kcsm, Sunitinib, business.industry, deferred, Cytoreduction Surgical Procedures, Sunitinib malate, medicine.disease, female genital diseases and pregnancy complications, Kidney Neoplasms, Surgery, immediate, Response Evaluation Criteria in Solid Tumors, #KidneyCancer, business, medicine.drug, cytoreductive nephrectomy

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9bc5c92c58ef9a01dd91f78a6279703Test
https://cris.maastrichtuniversity.nl/en/publications/ec77b0dc-0348-485f-8b49-ba17ccba249bTest

المؤلفون: Djura Piersma, Marye J Boers-Sonderen, Geke A. P. Hospers, Karijn P M Suijkerbuijk, Christian U. Blank, Roos S. van Rijn, Astrid A M van der Veldt, Jan-Willem B de Groot, Ellen Kapiteijn, Franchette W P J van den Berkmortel, Alfonsus J. M. van den Eertwegh, Jesper van Breeschoten, Doranne L. Hilarius, Bert-Jan J. ten Tije, Michel W.J.M. Wouters, Art Vreugdenhil, John B. A. G. Haanen, Maureen J.B. Aarts, Willeke A. M. Blokx

المصدر: Br J Cancer

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Cancer Research, business.industry, First line, Anti pd 1, Mutant, Correction, Cancer, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, business, Survival analysis, Advanced melanoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec07bf292a49af842f52b06a5d9be0e0Test
https://doi.org/10.1038/s41416-022-01772-zTest

المؤلفون: Alfonsus J. M. van den Eertwegh, Michel W.J.M. Wouters, Roos S. van Rijn, John B. A. G. Haanen, Maureen J.B. Aarts, Bert-Jan J. ten Tije, Karijn P M Suijkerbuijk, Christian U. Blank, Jesper van Breeschoten, Geke A. P. Hospers, Jan-Willem B de Groot, Franchette W P J van den Berkmortel, Ellen Kapiteijn, Doranne L. Hilarius, Marye J Boers-Sonderen, Djura Piersma, Art Vreugdenhil, Astrid A M van der Veldt, Willeke A. M. Blokx

المساهمون: VU University medical center, Obstetrics and gynaecology, Internal medicine, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Radiology & Nuclear Medicine, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9)

المصدر: British Journal of Cancer
British Journal of Cancer, 124(7), 1222-1230. Nature Publishing Group
British Journal of Cancer, 124, 7, pp. 1222-1230
British Journal of Cancer, 124, 1222-1230
van Breeschoten, J, Wouters, M W J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, Blokx, W A M, Tije, B-J J T, Veldt, A A M V D, Vreugdenhil, A, Boers-Sonderen, M J & van den Eertwegh, A J M 2021, ' First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis ', British Journal of Cancer, vol. 124, no. 7, pp. 1222-1230 . https://doi.org/10.1038/s41416-020-01229-1Test
British Journal of Cancer, 124(7), 1222-1230. SPRINGERNATURE

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, PHASE-3, First line, Systemic therapy, VEMURAFENIB, Article, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], POOLED ANALYSIS, Matched cohort, SDG 3 - Good Health and Well-being, Internal medicine, Medicine, METASTATIC MELANOMA, neoplasms, Melanoma, Survival analysis, Advanced melanoma, nivolumab, business.industry, IPILIMUMAB, Anti pd 1, medicine.disease, DABRAFENIB, Propensity score matching, pembrolizumab, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::836391be4c5b8d33487fc86cac6f6337Test
https://doi.org/10.1038/s41416-020-01229-1Test

المؤلفون: Christian U. Blank, Rodabe N. Amaria, Jennifer A. Wargo, Bart A. van de Wiel, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Alexander C. Huang, Xiaowei Xu, Richard A. Scolyer, Tara C. Mitchell, Giorgos C. Karakousis, Alexander C.J. van Akkooi, Michael A. Davies, Andrew J. Spillane, Elisa A. Rozeman, Alexander M. Menzies, Robyn P. M. Saw, Michael T. Tetzlaff, Ahmad A. Tarhini, Thomas E. Pennington, Elizabeth M. Burton, Paolo A. Ascierto, Serigne Lo

المصدر: Nature Medicine. 27:301-309

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Surrogate endpoint, Melanoma, medicine.medical_treatment, Ipilimumab, General Medicine, Immunotherapy, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Targeted therapy, Clinical trial, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, Nivolumab, business, Neoadjuvant therapy, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::826ffd3ff8235e1e6c027f5367069a0cTest
https://doi.org/10.1038/s41591-020-01188-3Test